河北秦皇岛FDACE认证

FDA对于美国代理人的解释也可以参考看一下的原文：
Any foreign establishment engaged in the manufacture, preparation, propagation, compounding, or processing of a device imported into the United States must identify a United States agent (U.S. agent) for that establishment.
Information about a foreign establishment’s U.S. Agent is submitted electronically using the FDA Unified Registration and Listing System (FURLS system) and is part of the establishment registration process. Each foreign establishment may designate only one U.S. agent. The foreign establishment may also, but is not required to, designate its U.S. agent as its official correspondent. The foreign establishment should provide the name, address, telephone and fax numbers, and e-mail address of the U.S. agent.
The U.S. agent identified will be required to complete an automated process to confirm that they have agreed to act as the U.S. agent. The automated process will forward an email verification request to the U.S. agent. They will be requested to confirm her/his consent to act as a representative/liaison on behalf of the foreign establishment. If the U.S. agent denies consent (or does not respond within 10 business days), the Official Correspondent/Owner Operator of the foreign establishment will be notified and must designate a new U.S. agent to satisfy the regulatory obligation.
Responsibilities of a U.S. agent
The U.S. agent must either reside in the U.S. or maintain a place of business in the U.S. The U.S. agent cannot use a post office box as an address. The U.S. agent cannot use an answering service. They must be available to answer the phone or have an employee available to answer the phone during normal business hours.
The responsibilities of the U.S. agent are limited and include:
assisting FDA in communications with the foreign establishment,
responding to questions concerning the foreign establishment's devices that are imported or offered for import into the United States,

美国食品药物管理局（FDA）正修订激光产品性能标准的提议向有关方征求意见；评议截止期为 9 月 23 日。该提议旨在：（i） 使当前标准与激光产品和医疗激光产品生产商已使用的国际标准更协调一致；（ii） 降低相关制造商的经济负担；（iii） 增强 FDA 对激光产品的有效性；（iv） 更好地保护和促进公众健康。

FDA建议修订适用于激光产品的《美国联邦法规》第 1 章，第 21 款的 J 节。因为当前激光产品性能标准的后一次更新是在 1985 年，是基于过时的光生物科学成果，已无法反映该技术性行业的现状。例如，目前广泛应用于半导体和通信行业的激光产品在上次标准更新时还未发明问世。FDA认证 的修订提议旨在使标准符合当前的科学发展状况，并使其与相关国际标准更协调一致。这些标准包括国际电工会（IEC）标准 60825–1《激光产品的—部分：设备分类和要求》（第二版，2007–03）；经 IEC 更正的 60825–1（第二版，2007），以及 IEC60601–2–22《医用电气设备—第二部分 2–22：、美容、治疗和诊断激光设备基本和基本性能的要求》（第三版，2007–05）。